Last updated: 2026-09-08 23:21:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Shattuck Labs, Inc. (STTK) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $6,51, with a market capitalization of $681,47M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,59 to $8,33. This page covers its latest market performance, valuation, price trends and company information.
$681,47M | |
$6,80 | |
$60,52 | |
$0,69 | |
$6,79 | |
877,80K | |
1,34M | |
-- | |
$8,33 | |
$1,59 | |
-- | |
-- |
Shattuck Labs, Inc. (STTK) is trading at $6,51 in after-hours trading as of 2026-09-08 23:18:00, down 4,20% ($0,29) from the regular-session close of $6,79.
After-hours trading shows how investors are pricing STTK after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Shattuck Labs, Inc. (STTK) moved from $7,65 to $6,51, representing a decline of 14,86% ($1,14).
The stock traded between $5,71 and $7,93 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 626,10 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 73,0%
STTK is currently trading at $6,51, placing it 73,0% of the way from its 52-week low of $1,59 to its 52-week high of $8,33. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 40 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Shattuck Labs, Inc. (STTK) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.